To what extent do patients in general practice reach guideline lipid-lowering treatment goals?

被引:3
作者
Kristiansson, Per
Bjoerholt, Ingela
Siewert-Delle, Annica
Svardsudd, Kurt
机构
[1] Uppsala Univ, Dept Publ Hlth & Caring Sci, Fac Med, Family Med & Clin Epidemiol Sect, SE-75185 Uppsala, Sweden
[2] Univ Gothenburg, Dept Surg, Inst Surg Sci, Gothenburg, Sweden
[3] AstraZeneca AB, Sodertalje, Sweden
来源
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION | 2007年 / 14卷 / 01期
关键词
lipid-lowering treatment statin treatment; treatment goals;
D O I
10.1097/HJR.0b013e3280125485
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background We assessed the extent to which the 1998 European guideline goals were reached among patients on statin treatment Design A cross-sectional study. Methods A total of 683 consecutive patients on statin treatment were recruited from 48 primary healthcare centres all over Sweden. Serum lipid levels and possible goal-reaching determinants were registered. Results The treatment goal for total cholesterol was met in 55% of patients and for low-density lipoprotein cholesterol in 60% of patients. Male sex and a history of diabetes mellitus or cardiovascular disease increased the likelihood of meeting treatment goals. Conclusions More than half of statin-treated Swedish primary care patients reached the treatment goals.
引用
收藏
页码:149 / 151
页数:3
相关论文
共 18 条
[1]  
BEERMAN B, 1995, NEW RECOMMENDATIONS, V3, P178
[2]   A British cardiac society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events) - Principal results [J].
Bowker, TJ ;
Clayton, TC ;
Ingham, J ;
McLennan, NR ;
Hobson, HL ;
Pyke, SDM ;
Schofield, B ;
Wood, DA .
HEART, 1996, 75 (04) :334-342
[3]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[4]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[5]   Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices [J].
Hippisley-Cox, J ;
Cater, R ;
Pringle, M ;
Coupland, C .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7391) :689-692
[6]   Risk factors in established coronary heart disease:: evaluation of a secondary prevention programme [J].
Kahan, T ;
Wändell, P .
JOURNAL OF CARDIOVASCULAR RISK, 2001, 8 (02) :73-80
[7]   Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries -: Principal results from EUROASPIRE II Euro Heart Survey Programme [J].
Kotseva, K ;
Wood, D ;
De Backer, G ;
De Bacquer, D ;
Pyöräla, K ;
Keil, U .
EUROPEAN HEART JOURNAL, 2001, 22 (07) :554-572
[8]   Clinical reality of coronary prevention guidelines:: a comparison of EUROASPIRE I and II in nine countries [J].
Kotseva, K ;
Wood, D ;
De Backer, G ;
De Bacquer, D ;
Pyörälä, K ;
Keil, U ;
Sans, S ;
Ambrosio, GB ;
Amouyel, P ;
Cokkinos, D ;
Deckers, JW ;
Erhardt, L ;
Graham, I ;
Gutzwiller, F ;
Keber, I ;
Keil, U ;
Lehto, S ;
Östör, E ;
Pajak, A ;
Sans, S ;
Simon, J ;
Turk, J ;
Wood, D ;
Wood, DA ;
Schofield, B ;
Bowker, T ;
Ingham, J ;
McLennan, N ;
Kotseva, K ;
Gollapalli, M ;
Valay, R ;
De Backer, G ;
De Bacquer, D ;
James, D ;
Mackness, M ;
Simon, J ;
Linhartová, K ;
Hafman, P ;
Mayer, O ;
Rosolova, H ;
Bocek, P ;
Hrncárek, M ;
Lupinek, P ;
Marek, T ;
Plaskova, M ;
Skodova, Z ;
Cifkova, R ;
Lehto, S ;
Lehto, R ;
Kemppainen, A .
LANCET, 2001, 357 (9261) :995-1001
[9]   Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease [J].
Majumdar, SR ;
Gurwitz, JH ;
Soumerai, SB .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1999, 14 (12) :711-717
[10]  
*MED PROD AG, 2003, MED PROD AG REC